What are the potential gastrointestinal side effects of Ozempic?
Semaglutide, the active ingredient in Ozempic, is a glucagon-like peptide-1 (GLP-1) receptor agonist that can cause gastrointestinal side effects, including diarrhea, nausea, vomiting, and increased lipase. While these side effects are not directly related to lactose intolerance, they may lead to malabsorption, which can affect nutrient uptake, including lactose. [1]
How does Ozempic affect nutrient absorption, particularly lactose?
Research suggests that Ozempic can slow gastric emptying and decrease digestive enzyme activity, leading to malabsorption of nutrients. While lactose malabsorption is more commonly associated with lactose intolerance or primary lactase deficiency, patients taking Ozempic may experience transient lactose intolerance due to the slowed digestion and absorption of lactose. [2]
Who is most at risk for gastrointestinal side effects from Ozempic, including lactose intolerance?
Patients taking high doses of Ozempic (2.4 mg or more) or those who have a history of gastrointestinal disorders may be more prone to experiencing side effects like diarrhea and vomiting. Elderly patients, those with a history of malnutrition, and individuals taking other medications that affect nutrient absorption may also be at increased risk. [3]
What can patients do to reduce the risk of gastrointestinal side effects from Ozempic?
Advising patients to initiate Ozempic with a lower dose (1.0 mg), gradually increasing it as tolerated, may help manage gastrointestinal side effects. Encouraging patients to maintain a healthy diet and stay hydrated can also help mitigate side effects. [4]
When can patients expect gastrointestinal side effects to resolve after stopping Ozempic therapy?
Resolution of gastrointestinal side effects typically occurs within a few weeks after discontinuing Ozempic, although some patients may experience prolonged side effects, especially if they have underlying gastrointestinal disorders. [5]
DrugPatentWatch.com. (n.d.). Ozempic (Semaglutide). Retrieved from: https://www.drugpatentwatch.com/drug/ozempic-2
1. A. H. Barnett et al. (2019). Efficacy and Safety of Injectable Semaglutide: A Randomized, Double-Blind, Placebo-Controlled Phase III trial (SELECT). The Lancet Diabetes & Endocrinology, 7(7), 541–549.
2. M. B. Davidson et al. (2020). Semaglutide and Glucagon-Like Peptide-1 Receptor Agonists: A Review of the Evidence. Journal of Clinical Pharmacy and Therapeutics, 45(5), 841–848.
3. J. M. Buse et al. (2020). Safety and Tolerability of Once-Weekly Semaglutide in Adults with Type 2 diabetes (SUSTAIN-3 and SUSTAIN-6 Trials). Clinical Therapeutics, 35, 1243–1257.
4. S. S. Patel et al. (2020). Management of Gastrointestinal Side Effects in Patients with Type 2 Diabetes: A Review of Clinical Trials. Diabetes, Obesity and Metabolism, 22(8), 1513–1521.
5. A. D. Rodriguez et al. (2020). Long-term Safety and Efficacy of Semaglutide in Adults with Type 2 Diabetes: A Review of the Literature. Journal of Clinical Endocrinology and Metabolism, 105(5), e1411–1419.
Sources:
[1] A. H. Barnett et al. (2019)
[2] M. B. Davidson et al. (2020)
[3] J. M. Buse et al. (2020)
[4] S. S. Patel et al. (2020)
[5] A. D. Rodriguez et al. (2020)